Giant-Cell Arteritis Therapeutics Market Size was ~USD 960 Million in 2023, is expected to increase by 2034 | DelveInsight

DelveInsight's "Giant-Cell Arteritis Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Giant-Cell Arteritis, historical and forecasted epidemiology as well as Giant-Cell Arteritis therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock key insights into the Giant-Cell Arteritis Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Giant-Cell Arteritis Market Size [https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Giant-Cell Arteritis Market Report

* In November 2024:- Novartis Pharmaceuticals- The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica. The study will consist of an up to 4-week screening period, an up to 2-year Treatment Period which includes two Treatment Periods, and a 16-week treatment-free follow-up period (20 weeks post last dose of secukinumab).
* In 7MM, the United States accounted for the highest number of diagnosed prevalent cases of Giant-Cell Arteritis, which is 54.0% of the diagnosed prevalent cases of Giant-Cell Arteritis in 2023.
* In the US, among the subtype-specific cases of Giant-Cell Arteritis, classic cranial Giant-Cell Arteritis cases were highest, followed by extracranial Giant-Cell Arteritis (large-vessel Giant-Cell Arteritis) cases in 2023.
* Among the EU4 and the UK, the United Kingdom accounted for the highest number of Giant-Cell Arteritis cases, followed by France, whereas Spain accounted for the lowest number of Giant-Cell Arteritis cases.
* In 2023, as far as clinical manifestation-specific cases are concerned, scalp tenderness accounted for the highest number of cases in Japan. These cases are anticipated to increase by 2034.
* The leading Giant-Cell Arteritis Companies such as AbbVie, Novartis Pharmaceuticals, CSL, Kiniksa Pharmaceuticals, Johnson & Johnson, MorphoSys AG , and others.
* Promising Giant-Cell Arteritis Therapies such as Mavrilimumab, Prednisone, Baricitinib, and others.

Stay ahead in the competitive landscape of the Giant-Cell Arteritis Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Giant-Cell Arteritis Treatment Market Size [https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Giant-Cell Arteritis Epidemiology Segmentation in the 7MM

* Giant-Cell Arteritis Diagnosed prevalent cases
* Giant-Cell Arteritis Region-specific cases
* Giant-Cell Arteritis Subtype-specific cases
* Giant-Cell Arteritis Gender-specific cases
* Giant-Cell Arteritis Age-specific cases
* Giant-Cell Arteritis Clinical manifestation-specific cases
* Total Giant-Cell Arteritis treated cases

Download the report to understand which factors are driving Giant-Cell Arteritis epidemiology trends @ Giant-Cell Arteritis Prevalence [https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Giant-Cell Arteritis Marketed Therapies

* ACTEMRA/ROACTEMRA (tocilizumab): Roche

ACTEMRA/ROACTEMRA (tocilizumab) is a first-in-class anti-IL-6 receptor (aIL-6R) therapy. IL-6 is believed to play a key role in activating the inflammatory pathway that contributes to the signs and symptoms of RA and other inflammatory autoimmune conditions. ACTEMRA/ROACTEMRA binds to the IL-6 receptor and blocks the inflammatory protein IL-6. This improves joint pain and swelling from arthritis and other symptoms caused by inflammation. It is also approved for the treatment of pediatric juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA), Giant-Cell Arteritis, and CAR-T cell-induced cytokine release syndrome (CRS).

Giant-Cell Arteritis Emerging Therapies

* RINVOQ (upadacitinib): AbbVie

RINVOQ (upadacitinib) is an orally administered selective and reversible Janus kinase (JAK) inhibitor; proinflammatory cytokines use immune signaling networks, such as the JAK-STAT pathway, to communicate with the cell nucleus. When dysregulated, these signals increase the inflammatory response, leading to cycles of chronic inflammation, presenting as pain, swelling, and progressive joint destruction. It is approved in the United States, Japan, and the European Union. RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs), is being developed by Abbvie.

* COSENTYX (secukinumab): Novartis Pharmaceuticals

COSENTYX (secukinumab) is an injectable fully human monoclonal antibody that specifically inhibits interleukin-17A (IL-17A), a cytokine involved in several immunological diseases, and is being developed by Novartis Pharmaceuticals. It is approved in the US and EU to treat patients with moderate-to-severe plaque psoriasis, adults with active ankylosing spondylitis (AS), adults with active non-radiographic axial spondyloarthritis (nr-axSpA), and adults with active psoriatic arthritis (PsA).

Discover the future of Giant-Cell Arteritis Treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ Giant-Cell Arteritis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Giant-Cell Arteritis Market Outlook

The term "Giant Cell" is used for the disease because when one looks at the biopsies of the inflamed temporal arteries under a microscope, it often appear as large or "giant" cells. The etiological factors of Giant-Cell Arteritis are a bit complex and still being widely researched, but yet it is not very well understood. Several factors that are understood till now may include genetic factors (HLA family), infectious or environmental factors, immune responses, and T-cell activation.

Giant-Cell Arteritis Treatment Market

The main goal of the treatment of Giant-Cell Arteritis is to prevent the patients from getting exposed to severe consequences of the disease, such as blindness. To treat Giant-Cell Arteritis, doctors may prescribe a high dose of corticosteroids, between 40 mg and 60 mg every day, which is continued for around 3-4 weeks. If the patient's condition starts to improve after that, the doctor will start reducing the dose. Although, there has always been a continuous discussion on the safety profile of corticosteroids. Other than corticosteroids, disease-modifying anti-rheumatic drugs (DMARDs) are also used sometimes to treat Giant-Cell Arteritis. DMARDs that are commonly used are methotrexate, leflunomide, and azathioprine.

Explore the dynamics of the Giant-Cell Arteritis Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Giant-Cell Arteritis Ongoing Clinical Trials Analysis [https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Giant-Cell Arteritis Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Giant-Cell Arteritis Companies- AbbVie, Novartis Pharmaceuticals, CSL, Kiniksa Pharmaceuticals, Johnson & Johnson, MorphoSys AG , and others.
* Giant-Cell Arteritis Therapies- Mavrilimumab, Prednisone, Baricitinib, and others.
* Giant-Cell Arteritis Therapeutic Assessment: Giant-Cell Arteritis Current Marketed and Giant-Cell Arteritis Emerging Therapies
* Giant-Cell Arteritis Market Dynamics: Giant-Cell Arteritis market drivers and Giant-Cell Arteritis market barriers
* Giant-Cell Arteritis Unmet Needs, KOL's views, Analyst's views, Giant-Cell Arteritis Market Access and Reimbursement

Table of Content

1. Key Insights

2. Report Introduction

3. Executive Summary of Giant-Cell Arteritis

4. Giant-Cell Arteritis Market Overview at a Glance

5. Disease Background and Overview

6. Diagnosis of Giant-Cell Arteritis

7. Diagnostic Guidelines

8. Treatment of Giant-Cell Arteritis

9. Treatment Guidelines

10. Epidemiology and Market Forecast Methodology

11. Epidemiology and Patient Population

12. Patient Journey

13. Marketed Therapies

14. Emerging Therapies

15. Giant-Cell Arteritis: Market Analysis

16. Unmet Needs

17. SWOT Analysis

18. KOL Views

19. Market Access and Reimbursement

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=giantcell-arteritis-therapeutics-market-size-was-usd-960-million-in-2023-is-expected-to-increase-by-2034-delveinsight]
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market



This release was published on openPR.